Impact of drugs approved for treating ADHD on the cell survival and energy metabolism: an in-vitro study in human neuronal and immune cells

Abstract

The oxidative and antioxidative properties of psychostimulants such as methylphenidate and amphetamine are discussed controversially. The aim of the present study was to evaluate the impact of psychostimulants and atomoxetine in different concentrations between 31.25 and 5000 ng/ml on the survival of human neuronal (neuroblastoma SH-SY5Y) and immune (monocytic U-937) cells and the impact of psychostimulants and atomoxetine in different concentrations between 500 and 5000 ng/ml on energy metabolism (adenosine triphosphate [ATP] content) in SH-SY5Y cells. Statistical analysis revealed that incubation for 24 h with amphetamine led to a significantly enhanced cell survival in both cell lines after treatment with various (32.5, 125, 250 and 1250 ng/ml) concentrations. Methylphenidate and atomoxetine induced a significantly enhanced cell survival at lower concentrations in the SH-SY5Y cell line, whereas in the U-937 cell line higher concentrations increased the cell survival. Incubation with the highest concentration of methylphenidate (5000 ng/ml) caused a significant reduction of cell survival in both cell types. Measurement of ATP contents in the neuronal cell line revealed no significant effects of the investigated compounds. Our results show that the examined substances exert concentration-dependent effects on cell survival in both applied cell lines.

Keywords

atomoxetine ATP cells psychostimulants survival

Get full access to this article

View all access options for this article.

References

Andreazza, AC , Frey, BN , Valvassori, SS , Zanotto, C. , Gomes, KM , Comim, CM , et al. (2007) DNA damage in rats after treatment with methylphenidate. Prog Neuropsychopharmacol Biol Psychiatry 31: 1282-1288.

Biederman, J. ( 2003) Pharmacotherapy for attention-deficit/ hyperactivity disorder (ADHD) decrease the risk for substance abuse: findings from a longitudinal follow-up youths with and without ADHD. J Clin Psychiatry 64(Suppl. 11): 3-8.

Buitelaar, JK , Danckaerts, M. , Gillberg, C. , Zuddas, A. , Becker, K. , Bouvard, M. , et al. (2004) A prospective, multicenter, open-label assesment of atomoxetine in non-North American children and adolsecents with ADHD. Eur Child Adolesc Psychiatry 13: 249- 257.

Castellanos, FX , Lee, PP , Sharp, W. , Jeffries, NO , Greenstein, DK , Clasen, LS , et al. (2002) Developmental trajectories of brain volume abnormalities in children and adolescents with attention-deficit/hyperactivity disorder. JAMA 288: 1740-1748.

Chan, P. , Di Monte, DA , Luo, JJ , DeLanney, LE , Irwin, I. , Langston, JW ( 1994) Rapid ATP loss caused by methamphetamine in the mouse striatum: relationship between energy impairment and dopaminergic neurotoxicity . J Neurochem 62: 2484-2487.

Fagundes, AO , Rezin, GT , Zanette, F. , Grandi, E. , Assis, LC , Dal-Pizzol, F. , et al. (2007) Chronic administration of methylphenidate activates mitochondrial respiratory chain in brain of young rats. Int J Dev Neurosci 25: 47-51.

Fleming, SM , Delville, Y. , Schallert, T. ( 2005) An intermittent, controlled-rate, slow progressive degeneration model of Parkinson’s diesease: antiparkinson effects of sineset and protective effects of methylphenidate. Behav Brain Res 156: 201-213.

Frey, BN , Martins, MR , Petronilho, FC , Dal-Pizzol, F. , Quevedo, J. , Kapczinski, F. ( 2006a) Increased oxidative stress after repeated amphetamine exposure: possible relevance as a model of mania. Bipolar Disord 8: 275-280.

Frey, BN , Valvassori, SS , Gomes, KM , Martins, MR , Dal-Pizzol, F. , Kapczinski, F. , et al. (2006b) Increased oxidative stress in submitochondrial particles after chronic amphetamine exposure. Brain Res 1097: 224-229.

10.

Frey, BN , Valvassori, SS , Reus, GZ , Martins, MR , Petronilho, FC , Bardini, K. , et al. (2006c) Changes in antioxidant defense enzymes after D-amphetamine exposure: implications as an animal model of mania. Neurochem Res 31: 699-703.

11.

Gomes, KM , Petronilho, FC , Mantovani, M. , Garbelotto, T. , Boeck, CM , Dal-Pizzol, F. , et al. (2008) Antioxidant enzyme activities following acute or chronic methylphenidate treatment in young rats. Neurochem Res 33: 1024-1027.

12.

Hubert, GW , Jones, DC , Moffett, MC , Rogge, G. , Kuhar, MJ ( 2008) CART peptides as modulators of dopamine and psychostimulants and interactions with the mesolimbic dopaminergic system. Biochem Pharmacol 75: 57-62.

13.

Jeng, W. , Wong, AW Ting-A-Kee, R. , Wells, PG ( 2005) Methamphetamine-enhanced embryonic oxidative DNA damage and neurodevelopmental deficits. Free Radic Biol Med 39: 317-326.

14.

Klöcking, R. , Schacke, M. , Wutzler, P. ( 1995) Primärscreening antiherpetischer Verbindungen mit EZ4U. Chemotherapie J 4: 141-147.

15.

Ludolph, AG , Schaz, U. , Storch, A. , Liebau, S. , Fegert, JM , Boeckers, TM ( 2006) Methylphenidate exerts no neurotoxic, but neuroprotective effects in vitro. J Neural Transm 113: 1927-1934.

16.

Mao, P. , Ardeshiri, A. , Jacks, R. , Yang, S. , Hurn, PD , Alkayed, NJ ( 2007) Mitochondrial mechanism of neuroprotection by CART. Eur J Neurosci 26: 624-632.

17.

Martins, MR , Reinke, A. , Petronilho, FC , Gomes, KM , Dal-Pizzol, F. , Quevedo, J. ( 2006) Methylphenidate treatment induces oxidative stress in young rat brain. Brain Res 1078: 189-197.

18.

Michelson, D. , Faries, D. , Wernicke, J. , Kelsey, D. , Kendrick, K. , Sallee, FR , et al.; Atomoxetine ADHD Study Group ( 2001) Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 108: E83.

19.

Pliszka, SR , Lancester, J. , Liotti, M. , Semrud-Clikeman, M. ( 2006) Volumetric MRI differences in treatment-naïve vs chronically treated children with ADHD. Neurology 67: 1023-1027.

20.

Reneman, L. , De Bruin, K. , Lavalaye, J. , Gunning, WB , Booij, J. ( 2001) Addition of a 5-HT receptor agonist to methylphenidate potentiates the reduction of [1231]FP-CIT binding to dopamine transporters in rat frontal cortex and hippocampus. Synapse 39: 193-200.

21.

Rogge, G. , Jones, D. , Hubert, GW , Lin, Y. , Kuhar, MJ ( 2008) CART peptides: regulators of body weight, reward and other functions. Nat Rev Neurosci 9: 747-758.

22.

Stopper, H. , Walitza, S. , Warnke, A. , Gerlach, M. ( 2008) Brief review of available evidence concerning the potential induction of genomic damage. J Neural Transm 115: 331-334.

23.

Swanson, JM , Sergeant, JA , Taylor, E. , Sonega-Barke, EJ , Jensen, PS , Cantwell, DP ( 1998) Attention-defecit hyperactivity disorder and hyperkinetic disorder. Lancet 351: 429-433.

24.

Teo, SK , Stirling, DI , Thomas, SD , Hoberman, AM , Christian, MS , Khetani, VD ( 2002) The perinatal and postnatal toxicity of D-methylphenidate and D, L-methylphenidate in rats. Reprod Toxicol 16: 353-366.

25.

Wu, B. , Hu, S. , Yang, M. , Pan, H. , Zhu, S. ( 2006) CART peptide promotes the survival of hippocampal neurons by upregulating brain-derived neurotrophic factor. Biochem Biophys Res Commun 347: 656-661.

26.

Yuan, J. , McCann, U. , Ricaurte, G. ( 1997) Methylphenidate and brain dopamine neurotoxicity. Brain Res 767: 172-175.